Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)
Status:
Unknown status
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
The Purpose of This Study is to Compare the Efficacy, Safety, Immunogenicity and
Pharmacokinetics between TQB2303 and Rituximab in Combination With CHOP in Previously
Untreated Patients with Diffuse Large B-cell Lymphoma
Phase:
Phase 3
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd